All In Biotech

Drug Trial Radar · NCT03399799

Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

64407564MMY1001: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

279

Actual

Start

Dec 16, 2017

Primary completion

Jul 7, 2022

Study completion Oct 20, 2027

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jan 16, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the safety of Talquetamab and to determine the recommended Phase 2 dose(s) (RP2Ds) and dosing schedule assessed to be safe for Talquetamab (Part 1 \[Dose Escalation\]) and to further characterize the safety of Talquetamab at the recommended Phase 2 dose(s) (RP2Ds) (Part 2 \[Dose Expansion\]).

Conditions

  • Hematological Malignancies

Interventions

  • TalquetamabDrug

    Participants will receive IV infusion or SC injection of Talquetamab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Dose-limiting Toxicity (DLT)Time frame: Up to Day 28
  2. Part 1 and Part 2: Number of Participants with Adverse Events (AEs) as a Measure of Safety and TolerabilityTime frame: From signing of Informed Consent Form (ICF) up to follow up (until 100 days after the last dose of study drug or until the start of subsequent anticancer therapy, if earlier [approximately 2.10 years])

Locations

13 sites in 4 countries. Site status is shown where the registry gives one.

  • University of Alabama Birmingham

    Birmingham, Alabama

  • City of Hope

    Duarte, California

  • University of Colorado Cancer Center

    Aurora, Colorado

  • Mount Sinai Medical Center

    New York, New York

  • Tennessee Oncology

    Nashville, Tennessee

  • Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman

    Liège, Belgium

  • VU Medisch Centrum

    Amsterdam, Netherlands

  • UMCU

    Utrecht, Netherlands

  • Hosp. Univ. Germans Trias I Pujol

    Badalona, Spain

  • Hosp Univ Fund Jimenez Diaz

    Madrid, Spain

  • Clinica Univ. de Navarra

    Pamplona, Spain

  • Hosp. Quiron Madrid Pozuelo

    Pozuelo de Alarcón, Spain

  • Hosp Clinico Univ de Salamanca

    Salamanca, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.